CML-155 Prognostic Markers of the Effectiveness of Tyrosine Kinase Inhibitors in Third-Line Therapy of Chronic Phase Chronic Myeloid Leukemia Patients: Data From a Multicenter Study

Tamara Chitanava,Vasily Shuvaev, Iuliia Matvienko,Irina Martynkevich,Sergey Voloshin,Elizaveta Efremova, Ekaterina Mileeva,Mikhail Fominykh, Anna Kersilova, Elena Koryagina,Natalia Ilyina, Natalia Dorofeeva,Nadezhda Medvedeva,Anna Klimovich,Tatiana Shneider,Svetlana Stepanova, Natalia Polezhajkovskaya, Nadiya Siordiya,Eugenia Sbityakova,Natalia Lazorko

Clinical Lymphoma Myeloma and Leukemia（2022）

Cited 0|Views9

No score

Abstract

Nearly a third of pts obtained CCyR on TKI-3L in our study. Most pts were alive at 5 years. Younger pts with any CyR on previous TKIs and at baseline had favorable prognosis. The use of TKI-3L is justified in low-risk groups and may be used in transplant-eligible pts.

Translated text

Key words

chronic myeloid leukemia,chronic phase,complete cytogenetic response,tyrosine kinase inhibitors,third-line therapy

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined